804 studies found for:    Open Studies | "Prostatic Neoplasms"
Show Display Options
Rank Status Study
21 Unknown  Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
Conditions: Cancer of the Prostate;   Prostate Cancer;   Prostatic Neoplasms
Interventions: Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E;   Drug: Placebo
22 Not yet recruiting Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Dietary Supplement: green tea extract;   Drug: quercetin;   Other: placebo;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
23 Recruiting Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Conditions: Castrate Resistant Prostate Cancer;   Chemotherapy Naive Prostate Cancer;   Prostate Cancer
Interventions: Drug: Pasireotide;   Drug: Everolimus;   Other: Laboratory biomarker analysis
24 Recruiting Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer
Conditions: Prostate Cancer Recurrent;   Stage II Prostate Carcinoma;   Stage III Prostate Carcinoma
Intervention: Device: PET/MR
25 Recruiting Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib on Bone Metastases in Patients With Castrate Resistant Prostate Cancer
Conditions: Bone Metastases;   Castrate-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: cabozantinib;   Other: laboratory biomarker analysis;   Procedure: magnetic resonance imaging
26 Recruiting Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Conditions: Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Drug: Akt inhibitor MK2206;   Drug: bicalutamide;   Other: clinical observation
27 Recruiting Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
Conditions: Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Radiation: stereotactic body radiation therapy;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
28 Recruiting Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression
Conditions: Prostatic Neoplasms;   Low Grade Prostate Cancer
Interventions: Other: Dietary intervention first;   Drug: Drug (Dutasteride) intervention first
29 Recruiting Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
Conditions: Prostatic Neoplasms;   Prostate Cancer
Intervention:
30 Recruiting Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: orteronel;   Other: laboratory biomarker analysis
31 Recruiting Enzalutamide With or Without Abiraterone Acetate and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: abiraterone;   Drug: prednisone
32 Recruiting Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Intervention: Biological: Ipilimumab
33 Recruiting Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate;   Drug: prednisone;   Drug: veliparib;   Other: laboratory biomarker analysis
34 Recruiting Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Bone Metastases;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Soft Tissue Metastases;   Stage IV Prostate Cancer
Interventions: Biological: sipuleucel-T;   Radiation: external beam radiation therapy;   Other: laboratory biomarker analysis
35 Recruiting NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
Conditions: Prostatic Neoplasms;   Prostate Cancer
Intervention: Drug: TAK-700
36 Recruiting Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer
Conditions: Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Other: active surveillance;   Drug: Sunphenon;   Other: laboratory biomarker analysis;   Other: Questionnaire Administration
37 Recruiting Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Other: pharmacological study
38 Recruiting Tivantinib in Treating Patients With Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: tivantinib;   Other: placebo;   Other: laboratory biomarker analysis
39 Recruiting Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: mifepristone;   Other: laboratory biomarker analysis;   Other: pharmacological study
40 Recruiting Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: degarelix;   Radiation: external beam radiation therapy;   Other: laboratory biomarker analysis

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years